Urinary Retention

07/01/2013 - "Dutasteride is an effective, safe and well-tolerated treatment either as monotherapy or in combination with an α-blocker, for the management of symptomatic BPH to improve symptoms, reduce the risk of acute urinary retention and risk for BPH-related surgery. "
02/01/2005 - "Randomised, placebo-controlled trials conducted over 2years have shown the efficacy of dutasteride in symptomatic relief, improvements in quality of life and peak urinary flow rate, and reduction of acute urinary retention events and the need for surgery. "
01/01/2005 - "Randomized placebo-controlled trials over 2 years have shown the efficacy of dutasteride in symptomatic relief, improvements in quality of life and peak urinary flow rate, and reduction of acute urinary retention events and need for surgery. "
01/01/2015 - "Pharmacological treatment with either drug results in similar symptom improvements; however dutasteride seems to have a better profile in reducing the risk of prostate surgery and acute urinary retention (AUR). "
09/01/2011 - "48 months, the incidence of acute urinary retention or BPH-related surgery was significantly less in the dutasteride group (2.5%) than in the placebo group (9%) overall (P<.001) and in each baseline prostate volume quintile (P<.01). "

09/01/2002 - "A significant reduction of residual urine was observed only occasionally, but at least alfuzosin is able to reduce the incidence of acute urinary retention. "
10/01/1999 - "Treatment with SR alfuzosin is effective in improving the success rate of a TWOC after an episode of acute urinary retention, although older patients are less likely to void successfully. "
10/01/2002 - "We conducted a study to evaluate the efficacy of using the alpha-blocker alfuzosin SR in patients with acute urinary retention. "
01/01/2005 - "Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study."
10/01/1999 - "In a prospective, randomized, placebo-controlled trial, 81 patients with acute urinary retention related to benign prostatic obstruction received either SR alfuzosin (n=40), an alpha1-selective blocker, given at a dose of 5 mg twice daily, or placebo (n=41) for 48 h. "

11/01/1987 - "There was a significantly greater incidence of urinary retention after morphine administration (P less than 0.05). "
05/01/1986 - "Urinary retention developed after the implantation in Case 2, but this improved following the reduction of morphine concentration. "
06/01/2013 - "The purpose of this study was to explore the relationship of postelective CD urinary retention and dose of spinal morphine. "
09/01/1988 - "A study of morphine-induced urinary retention in anesthetized rats capable of micturition."
06/01/1988 - "Intravenous cystogram for study of urinary retention following intrathecal morphine in unanesthetized rabbits."

01/01/2014 - "This study suggests that short perioperative treatment with tamsulosin can reduce the incidence of urinary retention and the need for catheterization after varicocelectomy, inguinal herniorrhaphy, and scrotal surgery."
01/01/2014 - "Effectiveness of tamsulosin in prevention of post-operative urinary retention: a randomized double-blind placebo-controlled study."
09/01/2015 - "Preemptive perioperative use of tamsulosin may significantly decrease the incidence of urinary retention in men undergoing pelvic surgery. "
09/01/2015 - "We aim to investigate the potential benefits of preemptive tamsulosin use on rates of urinary retention in men undergoing pelvic surgery. "
09/01/2015 - "Perioperative use of tamsulosin significantly decreases rates of urinary retention in men undergoing pelvic surgery."

06/01/2001 - "The present analysis from PLESS demonstrates that in both older (65 years old or older) and younger men with symptomatic BPH and enlarged prostates, finasteride is highly effective in improving symptoms and reducing prostate volume in many men and in reducing the risk of acute urinary retention and BPH-related surgery. "
01/01/2010 - "Finasteride consistently improved urinary symptom scores more than placebo in trials of > 1 year duration, and significantly lowered the risk of BPH progression (acute urinary retention, risk of surgical intervention, ≥ 4 point increase in the AUASI/IPSS). "
06/01/2001 - "In both age cohorts, finasteride treatment led to a 51% reduction (P <0.001) in the relative risk for acute urinary retention and/or BPH-related surgery, a significant (P <0.001) and durable improvement in symptom score, and a significant (P <0.001) and sustained reduction in prostate volume. "
07/01/2000 - "Randomised controlled trials have additionally demonstrated that finasteride therapy can provide improvement in terms of quality of life indices, prostate volume, and risks of progressing to acute urinary retention or prostatic surgery. "
12/01/2001 - "Long-term finasteride versus placebo studies, such as the PROSCAR Long-Term Efficacy and Safety Study (PLESS), suggest that long-term medical therapy with finasteride affects the natural history of the disease as manifested by the decrease in rates of acute urinary retention and surgery. "

10/01/1988 - "Phenoxybenzamine and urinary retention."
01/01/1988 - "In 21 of these 26 patients, urinary retention disappeared within 48 hours following phenoxybenzamine administration."
09/01/1985 - "Prophylactic phenoxybenzamine treatment is recommended as an alternative to routine bladder drainage in preventing urinary retention following vaginal repair operations for genital descensus."
03/01/1978 - "In one group of 21 patients who received phenoxybenzamine prophylactically only one patient had urinary retention develop; nine of 22 patients in the control group who did not receive prophylactic phenoxybenzamine postoperatively had urinary retention develop. "
01/01/1987 - "The efficacy of phenoxybenzamine in preventing postoperative urinary retention after total hip arthroplasty was investigated in a double-blind placebo-controlled study on 60 consecutive male patients with obstructive urinary symptoms. "

09/01/1984 - "There was a significantly greater incidence of urinary retention in the hospitalized patients who received long-acting regional anesthetic agents. "
12/01/1991 - "Perioperative fluid restriction and the use of short-acting anesthetics have been shown to be effective in decreasing postoperative urinary retention rates but are not applicable in all cases. "
02/01/2007 - "Perianal anesthetics infiltration allows the surgeons to perform anorectal surgery in a day-case regimen safely and effectively with a low incidence of urinary retention."
05/01/2005 - "These results suggest that the IUEC technique is a feasible and efficient method for providing anesthesia and analgesia for ACLR and is associated with a lower consume of anesthetics, less motor block and a reduced incidence of urinary retention."

12/01/2011 - "Initial combination treatment of anticholinergics plus α-blocker showed positive results for men with LUTS related to BPH and OAB symptoms and did not increase the risk of urinary retention."
02/01/2013 - "Two of the observational studies and a pooled analysis of randomized controlled trials reported a significant increase in the risk of acute urinary retention with inhaled anticholinergics. "
09/01/2012 - "Two case reports; 1 prospective, open-label, single-arm study; and 2 nested case-control studies evaluated or described the use of inhaled anticholinergic agents and the development of acute urinary retention in men with BPH/LUTS. "
09/01/2012 - "Randomized controlled trial data, observational studies, case reports, package labeling, and commentaries regarding men with BPH/LUTS using inhaled anticholinergic agents and the associated development of urinary retention were reviewed. "
01/01/2007 - "Increasing data and clinical experience support the efficacy and safety of anticholinergics in men; the rate of urinary retention has been equal to that of placebo in short-term studies. "

01/01/2006 - "The 5alpha-reductase inhibitors are effective in the long-term, especially in men with large prostates, and reduce the clinical progression of BPH, and further reduce the long-term risk of urinary retention and need for surgical intervention. "
03/01/2006 - "The purpose of this study was to assess the likelihood of having acute urinary retention (AUR) and prostate surgery after initiating therapy with an alpha blocker or 5-alpha reductase inhibitor in a real-world setting. "
09/01/2015 - "These estimates were performed only on patients taking medicinal products belonging to the 5 α-reductase inhibitors (5ARI) class that, although not indispensable, are the compounds that bring the greatest benefits, especially in the elderly and for which we know that every additional 30 days of therapy reduced the likelihood of acute urinary retention (AUR) and surgery by 14% and 11% respectively *. "
07/01/2015 - "According to the prostate volume (PV) ( < 80 or ≥ 80 ml), history of 5-alpha reductase inhibitor (5-ARI) medication, and history of acute urinary retention (AUR), we divided the patients into a PV < 80 ml, a PV ≥ 80 ml, a 5-ARI, a no 5-ARI; an AUR, and a no AUR group. "
01/01/2014 - "Moreover, 5α reductase inhibitors, alone or combined with an α adrenoceptor antagonist, can reverse the natural course of BPH, reducing the risk of urinary retention and the need for surgical intervention. "

12/01/1995 - "The self-reinforced polyglycolic acid spiral stent can effectively and safely prevent postoperative urinary retention after visual laser ablation of the prostate."
01/01/1997 - "The self-reinforced polyglycolic acid spiral stent is superior to the suprapubic catheter alone, and to combined indwelling and suprapubic catheters for the treatment of postoperative urinary retention after laser therapy, offering possibilities for shorter catheterization time."
01/01/1997 - "A randomized controlled study was done to evaluate the efficacy of the self-reinforced polyglycolic acid spiral stent compared to a suprapubic catheter, and combined suprapubic and indwelling catheters in the prevention of urinary retention after visual laser ablation of the prostate. "
12/01/1995 - "Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy."
08/01/2000 - "The present randomized study was carried out to investigate the feasibility and efficacy of a biodegradable self-reinforced polyglycolic acid (SR-PGA) stent in preventing postoperative urinary retention and the need for prolonged catheterization after ILC treatment. "

12/01/2013 - "Patients who had pre-operative urinary retention and catheter at the time of surgery had significant improvement in both subjective (IPSS ,p=.oo4) and objective (maximum & average flow rates p=.04) parameters studied. "
03/01/2007 - "The prevalence of IDC/DH-IDC was significantly greater in those with a history of urinary retention and an indwelling urethral catheter. "
12/01/2012 - "Improved techniques for catheter placement are essential for all healthcare personnel involved in the management of the patient with acute urinary retention, including attending emergency physicians who often are the first physicians to encounter such patients. "
12/13/2007 - "If surgery was impossible, the urinary retention could be relieved with a catheter. "
02/01/1995 - "Only 4 patients complained of transient urinary retention, although another 3 or 5 days catheter placement relieved their symptoms. "

08/01/2007 - "In this study, the risk of urinary retention due to BPH was significantly greater in men with ACI than in those without, and the association of TURP for retention with ACI was stronger than that with prostate weight. "
09/01/2003 - "Because all medication was ineffective, transurethral resection of prostate was performed on 11 January, 2002, but urinary retention could not be relieved. "
04/01/2013 - "The objective of this study was to investigate whether bladder filling with saline prior to trial of void (TOV) was safe and whether it reduced time to discharge compared with standard TOV in the urology inpatient setting for patients post-transurethral resection of prostate, bladder neck incision or an admission with urinary retention. "
03/01/2012 - "• Symptom severity and acute urinary retention/transurethral resection of the prostate (AUR/TURP) event data came from the 4-year evaluation of the CombAT trial with additional data from the Medical Therapy of Prostatic Symptoms (MTOPS) trial. "
07/01/2006 - "Patients were included in the study if an International Classification of Diseases, Tenth Revision code for acute urinary retention or an operative procedure code for transurethral prostate resection was present in any diagnosis or procedure fields of the Hospital Episode Statistics database. "

07/01/2000 - "Transurethral prostatic resection is more effective than laser ablation in men with chronic urinary retention in terms of symptom score, maximum urinary flow and failure. "
08/01/2011 - "• To evaluate the safety and efficacy of laser vaporization of the prostate (LVP) with several different wavelengths for urinary retention. "
07/01/2001 - "Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial."
07/01/2000 - "A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study."
08/01/2011 - "Prostate laser vaporization in men with urinary retention."

01/01/2004 - "Recent studies have demonstrated that prostatic stents are effective in relieving obstruction and urinary retention. "
04/01/1992 - "Evaluation on the basis of improvement in MFR and reduction in RU showed that the stent was effective in 71% of total patients (22 out of 31 patients), 94% of the patients with urinary retention (17 out of 18 patients). "
05/01/2003 - "As a results of this study, the Memotherm stent is good conservative therapy for high-risk urinary retention patients."
09/01/2000 - "The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle((R)), Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable. "
12/01/2012 - "Temporary prostatic urethral stents that are used for the management of urinary retention may also be used for evaluation of patients with detrusor hypo-contractility. "

08/01/2001 - "To investigate the utility of "late" pressure-flow studies in predicting the outcome of prostatectomy for acute urinary retention. "
05/01/1998 - "The study included 3966 men undergoing prostatectomy, of whom 1242 presented with acute urinary retention; the complication rates and symptomatic outcome were assessed. "
08/01/2014 - "While urinary retention is a known complication of AdVance male sling (AMS) placement for post-prostatectomy incontinence (PPI), there is minimal data regarding ultimate continence outcomes for patients who experience this complication. "
04/01/2013 - "Acute urinary retention develops infrequently after robotic prostatectomy. "
04/01/2013 - "Risk and prevention of acute urinary retention after robotic prostatectomy."